UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|--------------------------|---------------------------------|----------------------|---------------------|------------------|
| 10/583,286 | 06/16/2006 | Yoshio Yamauchi | IWI-16646 | 9818 |
| | 7590 11/05/200 L & CLARK LLP | | EXAMINER | |
| 925 EUCLID A | VENUE, SUITE 700 | | SHEN, BIN | |
| CLEVELAND, OH 44115-1405 | | | ART UNIT | PAPER NUMBER |
| | | | 1657 | |
| | | | | |
| | | | MAIL DATE | DELIVERY MODE |
| | | | 11/05/2008 | PAPER |

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

| | Application No. | Applicant(s) | | | |
|---|---|--|--|--|--|
| | 10/583,286 | YAMAUCHI ET AL. | | | |
| Office Action Summary | Examiner | Art Unit | | | |
| | BIN SHEN | 1657 | | | |
| The MAILING DATE of this communication app Period for Reply | ears on the cover sheet with the c | orrespondence address | | | |
| A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). | ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE | N. nely filed the mailing date of this communication. D (35 U.S.C. § 133). | | | |
| Status | | | | | |
| Responsive to communication(s) filed on 16 Ju This action is FINAL . 2b) ☑ This Since this application is in condition for allowar closed in accordance with the practice under E | action is non-final. nce except for formal matters, pro | | | | |
| Disposition of Claims | | | | | |
| 4) ☐ Claim(s) 1-3 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1-3 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or Application Papers 9) ☐ The specification is objected to by the Examine 10) ☐ The drawing(s) filed on is/are: a) ☐ access applicant may not request that any objection to the orange. | r election requirement. r. epted or b)⊡ objected to by the B drawing(s) be held in abeyance. See | e 37 CFR 1.85(a). | | | |
| Replacement drawing sheet(s) including the correcti 11) The oath or declaration is objected to by the Ex | | | | | |
| Priority under 35 U.S.C. § 119 | | | | | |
| 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. | | | | | |
| Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 9/12/2006, 7/9/2007, 8/29/2008. | 4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other: | nte | | | |

Application/Control Number: 10/583,286 Page 2

Art Unit: 1657

DETAILED ACTION

The IDS received 9/12/2006, 7/9/2007, and 08/29/2008, have been entered. Claims 1-3 are presented for examination on the merits.

Specification

The abstract of the disclosure is objected to because the abstract must be a single paragraph. Correction is required. See MPEP § 608.01(b).

Applicant is reminded of the proper language and format for an abstract of the disclosure.

The abstract should be in narrative form and generally limited to a single paragraph on a separate sheet within the range of 50 to 150 words. It is important that the abstract not exceed 150 words in length since the space provided for the abstract on the computer tape used by the printer is limited. The form and legal phraseology often used in patent claims, such as "means" and "said," should be avoided. The abstract should describe the disclosure sufficiently to assist readers in deciding whether there is a need for consulting the full patent text for details.

The language should be clear and concise and should not repeat information given in the title. It should avoid using phrases which can be implied, such as, "The disclosure concerns," "The disclosure defined by this invention," "The disclosure describes," etc.

The use of the trademark "ICAT" on page 2 has been noted in this application. They should be capitalized wherever they appear and be accompanied by the generic terminology.

Although the use of trademarks is permissible in patent applications, the proprietary nature of the marks should be respected and every effort made to prevent their use in any manner which might adversely affect their validity as trademarks.

Claim Objections

Claim 1 is objected to because of the following informalities: "digestting" is a misspelling on line 6. Appropriate correction is required.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

Application/Control Number: 10/583,286 Page 3

Art Unit: 1657

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 1 and 3 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Where applicant acts as his or her own lexicographer to specifically define a term of a claim contrary to its ordinary meaning, the written description must clearly redefine the claim term and set forth the uncommon definition so as to put one reasonably skilled in the art on notice that the applicant intended to so redefine that claim term. *Process Control Corp. v. HydReclaim Corp.*, 190 F.3d 1350, 1357, 52 USPQ2d 1029, 1033 (Fed. Cir. 1999). The term "restriction enzyme" in claim1, line 7 is used by the claim to mean "protease", while the accepted meaning is "enzymes that cleave polynucleotides." The term is indefinite because the specification does not clearly redefine the term. Hence the metes and bounds of the claims are not clear.

In this action, "restriction enzyme" is interpreted by the Examiner as protease that cleaving polypeptides instead of cleaving polynucleotides, thus the following rejections apply.

Claim 3 recites "naturally-occurring isotope" which lacks antecedent basis. Claim 2 recites "stable isotope". Even unstable isotopes like ¹⁴C are naturally occurring.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Application/Control Number: 10/583,286 Page 4

Art Unit: 1657

Claim 1 is rejected under 35 U.S.C. 102(b) as being anticipated by Goshe (2003).

Goshe teaches a method for analyzing protein including the steps of: digesting two types of samples (page 102 Fig. 1: proteolysis step); modifying peptides with labeling compounds (page 102 Fig. 1: labeling step); mixing, separating and quantifying the samples and measuring the MS spectrum, and finding the content ratio of peptides; selecting a peptide; identifying a corresponding protein; finding the ratio of the content of identified protein (page 102 Fig. 1: last step).

Therefore, the cited reference is deemed to anticipate the instant claims above.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-3 are rejected under 35 U.S.C. 103(a) as being unpatentable over Goshe (2003) in view of Brancia (2004).

Art Unit: 1657

Goshe teach what is above, in addition to the teaching of the increase or decrease in the abundance ratio provides information on protein (read as the quantitative ratio is corrected by getting rid of the overlapping region-increase or decrease: see legend on page 102, end of Fig. 1).

Page 5

Goshe does not teach using O-methyl-isourea and its stable isotopes as labeling compounds.

However, Goshe teaches many other compounds that can be used as labeling compounds (page 103, Table 1, and page 103, right column, 2nd full paragraph).

Brancia teaches the use of O-methyl-isourea and its stable isotope as labeling compounds (abstract, lines 5-7).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the method of Goshe by choosing O-methyl-isourea as labeling compound because Goshe teaches alternative stable isotope labeling (page 103, right column, 2nd full paragraph) and Brancia teaches the use of O-methyl-isourea and its stable isotope as labeling compounds. One would have been motivated to make the modification because both Goshe and Brancia teach a method of analyzing proteins with MS spectrum, and O-methyl-isourea contains N-, C-, etc., that can results in light and heavy labelings (see page 102, Fig. 1 and page 103, Table 1), and thus the labeling compounds are art recognized equivalents, and would reasonably have expected success in view of Brancia's teaching of O-methyl-isourea as labeling compounds (abstract).

From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention.

Therefore, the invention as a whole was *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

Conclusion

No claim is allowed.

Certain papers related to this application may be submitted to Art Unit 1657 by facsimile transmission. The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. § 1.6(d)). The official fax telephone number for the Group is 571-273-8300. NOTE: If

Application/Control Number: 10/583,286

Art Unit: 1657

Applicant *does* submit a paper by fax, the original signed copy should be retained by applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

Page 6

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Any inquiry concerning rejections or objections in this communication or earlier communications from the examiner should be directed to Bin Shen, Ph.D., whose telephone number is (571) 272-9040. The examiner can normally be reached on Monday through Friday, from about 9:00 AM to about 5:30 PM. A phone message left at this number will be responded to as soon as possible (i.e., shortly after the examiner returns to her office).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Jon Weber can be reached at (571) 272-0925.

B Shen

Art Unit 1657

JON P WEBER/

Supervisory Patent Examiner, Art Unit 1657